anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cholangiocarcinoma (CCA) is one of the most difficult malignancies to treat as the therapeutic options are limited. Although several driver genes have been identified, most remain unknown. In this study, we identified a failed axon connection homolog (FAXC), whose function is unknown in mammals, by analyzing serially passaged CCA xenograft models. Knockdown of FAXC reduced subcutaneous tumorigenicity in mice. FAXC was bound to annexin A2 (ANXA2) and c-SRC, which are tumor-promoting genes. The FAXC/ANXA2/c-SRC complex forms in the mitochondria. FAXC enhances SRC-dependent ANXA2 phosphorylation at tyrosine-24, and the C-terminal amino acid residues (351-375) of FAXC are required for ANXA2 phosphorylation. Transcriptome data from a xenografted CCA cell line revealed that FAXC correlated with epithelial-mesenchymal transition, hypoxia, and KRAS signaling genes. Collectively, these findings advance our understanding of CCA tumorigenesis and provide candidate therapeutic targets.
The invention relates to a method for the preparation of 2-[4-[2-(1-piperidinyl)ethoxy] benzoyl] benzoic acid methyl ester hydrochloride having antispasmolytic activity and strong local anaesthetic effect and is used as antispasmolytic component in medicamentous compositions in combination with analgetics. By the method, a high purity and high yield product is turned out in reaction between phenol and dichlorethane, acylation of the phenyloxyethylchloride produced and subsequent amination with piperidine in aqueous-alkaline medium at 100 degrees C of an influx. After the water distillation the remainder is cooled to room temperature and is esterified with methanol and sulphuric acid at 65 to 75 degrees C. After the elimination of the methanol excess, the remainder of the reaction mixture is diluted in water and is neutralized to pH 7-8 at continuous cooling. The ester produced is extracted by dichlorethane, the extract is evaporated, and the residue is dissolved in acetone, hydrochloric acid is added, and the reaction mixture is cooled to 0-5 degrees C. The sediment produced is filtered, washed in acetone, is dried and purified in ethanol. The purified product crystallizes by the addition of acetone and cooling to 0-5 degrees C and is then dried. 2 claims
The present invention discloses a health care spirit, which relates to a spirit. The present invention aims to solve the problem that the existing medicated spirit for treating trachitis does not have a health care function. The present invention is prepared from 3 to 7 parts by weight of dahurian rhododendron leaf, 1 part by weight to 5 parts by weight of double blossom, 3 to 7 parts by weight of platycodon, 0.1 to 1 part by weight of safflower, 2 to 6 parts by weight of rock candy, 2 to 6 parts by weight of honey and 90 to 110 parts by weight of spirit. The preparation method of the present invention comprises: the dahurian rhododendron leaves, the double blossom, the platycodon, the safflowers, the rock candy and the honey are soaked in the spirits in a container for 15 to 30 days according to the parts by weight, and the filtered liquid is the health care spirit of the present invention. Medicine effect is difficult to reach the trachea and the bronchia, because the spirits can promote the blood circulation, the medicines of the present invention are brought to the trachea and the bronchia by the spirits, and the health care effect on the trachea and the bronchia is realized. The present invention has the advantages that the present invention has double efficacy of cold resistance and health care, and is main used for preventing trachitis and bronchitis or relieving symptoms of trachitis and bronchitis; the present invention has exact and obvious health care effect and does not have toxic or side effect.
This invention relates to beauty products for exfoliation. Previously, exfoliation and body cream application was inefficient. Embodiments of the present invention use an exfoliation and body cream application mitt (10) that is configured to apply a thickened liquid to a human user. The exfoliation and body cream application mitt has a back side (12) and a front side (14) joined to one another forming a pocket therebetween. The front side is adapted to accomplish exfoliation and the back side is adapted to accomplish lotion application. A soft fabric is arranged within the back side and is configured to gently spread body creams, foams and lotions to a skin surface. A wrist section is arranged between the back side and the front side, defining an opening for receiving a hand of a user.
Electrophysiological study (EPS) is essential tool for heart rhythm disorders diagnostic. Inducibility of arrhythmia before ablation to confirm the diagnosis and inability to do so after the procedure is crucial for long-term success. Multiple drugs are used to reveal arrhythmias and/or conductive system disorders. Two most often used are atropine and isoprenaline. Atropine is a natural, selective antagonist of cholinergic receptors M1 and M2. It reverses the inhibitory effect of vagal nerve on myocardium. This improves sinus node automatism and conduction in atrioventricular node. Isoprenaline is a preferential agonist of beta-1-adrenergic receptors. It has bathmotropic and chronotropic effect. During daily clinical practice those two drugs are often used interchangeably. However, differences in pharmacokinetics and pharmacodynamics may affect the results. There are lack of data directly comparing those two agents. There are isolated evidences that arrhythmia inducibility rate after the ablation differs between those two drugs. This may lead to the misconception of ablation as successful. The aim of presented study is to evaluate the optimal protocol of pharmacotherapy during EPS.
Measurement of auricle parameters for planning and post-operative evaluation presents substantial challenges due to the complex 3D structure of the human auricle. Traditional measurement methods rely on manual techniques, resulting in limited precision. This study introduces a novel automated surface-based three-dimensional measurement method for quantifying human auricle parameters. The method was applied to virtual auricles reconstructed from Computed Tomography (CT) scans of a cadaver head and subsequent measurement of important clinically relevant aesthetical auricular parameters (length, width, protrusion, position, auriculocephalic angle, and inclination angle). Reference measurements were done manually (using a caliper and using a 3D landmarking method) and measurement precision was compared to the automated method. The CT scans were performed using both a contemporary high-end and a low-end CT scanner. Scans were conducted at a standard scanning dose, and at half the dose. The automatic method demonstrated significantly higher precision in measuring auricle parameters compared to manual methods. Compared to traditional manual measurements, precision improved for auricle length (9×), width (5×), protrusion (5×), Auriculocephalic Angle (5-54×) and posteroanterior position (23×). Concerning parameters without comparison with a manual method, the precision level of supero-inferior position was 0.489 mm; and the precisions of the inclination angle measurements were 1.365 mm and 0.237 mm for the two automated methods investigated. Improved precision of measuring auricle parameters was associated with using the high-end scanner. A higher dose was only associated with a higher precision for the left auricle length. The findings of this study emphasize the advantage of automated surface-based auricle measurements, showcasing improved precision compared to traditional methods. This novel algorithm has the potential to enhance auricle reconstruction and other applications in plastic surgery, offering a promising avenue for future research and clinical application.
Carboplatin (AUC = 5, d1) and nab-paclitaxel (175 mg/m², day1) will be administered every 3 weeks for four cycles.Tislelizumab (200 mg) will be administered every 3 weeks for up to 12 months. Radiotherapy targeting esophageal lesions and positive lymph nodes, with a total dose of 50.4 Gy over 28 fractions will be delivered.
The gold standard for the diagnosis of sleep breathing disorders is polysomnography (PSG), which requires contact sensors, in-lab monitoring and manual scoring by experts, limiting the comfortability of patients and accessibility of diagnosis. A novel contactless millimeter-wave radar-based Sleep Respiratory Monitoring System is developed, in order to assist sleep staging and the diagnosis of sleep breathing disorders.

The Sleep Respiratory Monitoring System is capable of collecting, recording, storing and analyzing breathing, heartbeat, spatial distribution of full-body movements, etc. via a millimeter-wave radar, and oxygen saturation, pulse, etc. via a pulse oximeter. A dedicated algorithm enables the system to detect respiratory events and estimate sleep stages based on the collected data. The device and algorithms are to be validated in this study by comparison with PSG.
Following baseline microcirculatory and blood pressure measurements, as well as the collection of urine and saliva samples, participants on the "beetroot" group were asked to consume 140ml beetroot juice (James White Drinks Company, Suffolk, UK). The 140 ml of beetroot juice equate to approximately 8.4 mmol of NO3- .
People with hematological malignancies or solid tumors in various phases of their treatment (under treatment or in remission/ follow-up). This cohort may include patients with smoldering multiple myeloma (n=50), multiple myeloma (n=140), chronic lymphocytic leukemia (with or without hypoglobulinemia) (n=50), lymphoma (n=80), AL amyloidosis (n=30), patients who receive PARP (n=30), CDK4/6 (n=30), or immune checkpoint inhibitors (n=40), and patients under therapy with Androgen Receptor Targeted Agents (n=50).
The invention discloses applications of a CO2 supercritical fluid extraction product of centipeda minima in preparation of anti-influenza virus medicines or food. The extraction product of the centipeda minima is an extraction product obtained by utilization of a CO2 supercritical fluid extraction technology, or an extraction product which is obtained by subjecting the extraction product obtained by the CO2 supercritical fluid extraction technology to extraction and purification by petroleum ether, cyclohexane, chloroform or benzene. The extraction product of the centipeda minima has good anti-influenza virus functions. The antivirus function of the extraction product of the centipeda minima is equivalent to or more significant than that of positive control ribavirin. The extraction product of the centipeda minima has good medical application value. The applications provided by the invention provide a powerful technological base for development of the centipeda minima plant resource.
SARS-CoV-2 has been shown to cause wide-ranging ocular abnormalities and vision impairment in COVID-19 patients. However, there is limited understanding of SARS-CoV-2 in ocular transmission, tropism, and associated pathologies. The presence of viral RNA in corneal/conjunctival tissue and tears, along with the evidence of viral entry receptors on the ocular surface, has led to speculation that the eye may serve as a potential route of SARS-CoV-2 transmission. Here, we investigated the interaction of SARS-CoV-2 with cells lining the blood-retinal barrier (BRB) and the role of the eye in its transmission and tropism. The results from our study suggest that SARS-CoV-2 ocular exposure does not cause lung infection and moribund illness in K18-hACE2 mice despite the extended presence of viral remnants in various ocular tissues. In contrast, intranasal exposure not only resulted in SARS-CoV-2 spike (S) protein presence in different ocular tissues but also induces a hyperinflammatory immune response in the retina. Additionally, the long-term exposure to viral S-protein caused microaneurysm, retinal pigmented epithelium (RPE) mottling, retinal atrophy, and vein occlusion in mouse eyes. Notably, cells lining the BRB, the outer barrier, RPE, and the inner barrier, retinal vascular endothelium, were highly permissive to SARS-CoV-2 replication. Unexpectedly, primary human corneal epithelial cells were comparatively resistant to SARS-CoV-2 infection. The cells lining the BRB showed induced expression of viral entry receptors and increased susceptibility towards SARS-CoV-2-induced cell death. Furthermore, hyperglycemic conditions enhanced the viral entry receptor expression, infectivity, and susceptibility of SARS-CoV-2-induced cell death in the BRB cells, confirming the reported heightened pathological manifestations in comorbid populations. Collectively, our study provides the first evidence of SARS-CoV-2 ocular tropism via cells lining the BRB and that the virus can infect the retina via systemic permeation and induce retinal inflammation.
A tattooing device for producing a temporary predetermined image on the human skin by the action of skin tanning rays comprises a template having a laminated structure which comprises a flexible first layer and a removable second layer. A central opening which is defined in the laminated structure of the template has an outline which corresponds to the image. A first surface of the first layer is provided with an adhesive with the second layer being removably mounted to this first surface. Upon removal of the second layer from the first layer, the latter is applied on the skin at a desired location. A sun block is then distributed on the skin within the central opening. Removal of the first layer from the skin leaves sun block thereon which corresponds to the desired image. Once the skin has been exposed to tanning rays, the sun block is washed away from the skin thereby revealing a skin tattoo. The present invention can also be presented in a kit which includes a series of templates defining central openings having one or more different shapes to produce various images. The kit further includes a sun block such as a colored zinc oxide based cream or lotion. A method for using the present invention is also presented.
The pharmacodynamic effects of GIVLAARI were evaluated in chronic high excreters treated with 0.035 to 2.5 mg/kg single dose and AHP patients treated with 2.5 to 5 mg/kg once monthly and 2.5 to 5 mg/kg once quarterly dose via subcutaneous injection. Dose-dependent reduction in urinary ALAS1 mRNA, ALA and PBG levels was observed over the 0.035 to 5 mg/kg dose range (0.14 to 2-fold the approved recommended dosage). Median reductions from baseline in urinary ALA and PBG of 83.7% and 75.1%, respectively, were observed 14 days after the first dose of GIVLAARI 2.5 mg/kg once monthly in AHP patients. Maximal reductions in ALA and PBG levels were achieved around Month 3, with median reductions from baseline of 93.8% for ALA and 94.5% for PBG, and were sustained thereafter with repeated once monthly dosing.

Cardiac Electrophysiology

The effect of GIVLAARI on the QTc interval was evaluated in a double-blind, placebo-controlled study and the open-label extension in 94 patients. No large mean increase in QTc (i.e. >20 ms) was detected at the 2.5 mg/kg once monthly dose level. A dedicated thorough QT study has not been conducted with GIVLAARI.
This invention relates to a 4-oxybenzopyran derivative of formula (I) wherein, R?1 and R2¿ represent each independently a hydrogen atom, a C¿1-6? alkyl group or a phenyl group; R?3¿ represents a hydroxyl group or C¿1-6? alkylcarbonyloxy group; R?4¿ represents a hydrogen atom, a C¿3-6? cycloalkyl group, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkylaminocarbonyl group, a di-C1-6 alkylaminocarbonyl group, an aryl group or a heteroaryl group; R?5¿ represents a hydrogen atom or a C¿1-6? alkyl group; X is absent or represents C=O or SO2; R?6¿ represents a hydrogen atom, a C¿1-6? alkyl group or a C3-6 cycloalkyl group; R?7¿ represents a hydrogen atom, a halogen atom, a nitro group or a cyano group; or a pharmaceutically acceptable salt thereof. And this invention also relates to a drug for treating arrhythmia having the prolongation effect on the functional refractory period comprising said compound or a pharmaceutically acceptable salt thereof as an active ingredient.
OBJECTIVES: I. Compare the relative efficacy of oral uracil/tegafur (UFT) with leucovorin (CF) vs. fluorouracil (5-FU) with CF in prolonging overall and disease-free survival in patients with potentially curatively resected stage II/III adenocarcinoma of the colon. II. Compare the prognostic significance of several biomarkers alone or in combination, including DNA mismatch repair gene mutations, p53, deleted colon cancer gene, proliferation status, and thymidylate synthase, in patients treated with UFT/CF vs. 5-FU/CF. III. Evaluate the relationships of various biomarkers to each other and their association with patient and tumor characteristics. IV. Compare quality of life in patients treated with UFT/CF vs. 5-FU/CF.

OUTLINE: This is a randomized study. Patients are stratified by number of positive lymph nodes and participating institution. For the quality-of-life portion of the study, patients are stratified by age, sex, and ethnicity. Treatment begins within 6 weeks after curative resection and within 1 week of randomization. Patients are randomly assigned to one of two groups. The first group receives intravenous leucovorin followed by intravenous fluorouracil weekly for 6 weeks. Treatment repeats every 8 weeks for a total of 3 courses. The second group receives oral uracil/tegafur, and oral leucovorin every 8 hours for 28 days. Treatment repeats every 5 weeks for a total of 5 courses. No concurrent halogenated antiviral agents (e.g., sorivudine) are permitted. After completing treatment, patients complete quality-of-life questionnaires at one year.

PROJECTED ACCRUAL: Approximately 1,500 patients will be entered over 3 years to provide 1,452 evaluable patients.
Lung cancer is the leading cause of cancer-related death globally, with poor survival rates due mostly to a lack of early detection. The usual diagnostic technique includes a biopsy, which is frequently performed later in the disease's progression. In order to uncover processes that improve illness detection and prognosis, miRNA-21 emerges as a major miRNA identified in a variety of cancer types, including lung cancer. This review compiles insights into the involvement of miRNA-21 within the distinct cellular processes underlying lung cancer. To achieve this, we conducted an extensive literature review, drawing from published in vitro, in vivo and clinical trials studies. Searches were performed in the PubMed, Scielo, CAPES Journal Portal, BVS, INCA, and Clinical Trials.Gov. Only English written articles were selected. As screening criteria, we selected articles that explored the modulation pathways of miRNA-21, along with the proteins and genes implicated in tumorigenesis, metastasis, therapy resistance to established treatments, and their significance in the diagnosis and prognosis of lung cancer. A total of 3294 articles were identified, and 37 papers were selected to compose the review, after analysing selection criteria. Of these, 57 % studies presented in vitro evaluation, 22 % studies showed in vivo analysis, and 12 clinical trials were found. This study elucidates the principal signaling pathways influenced by miRNA-21, which play a pivotal role in lung cancer development. This comprehensive review sheds light on the potential significance of miRNA-21 as a critical mechanism for improving the prognosis of lung cancer patients, facilitating the transition of experimental data into the clinical phase. Therefore, we summarized published articles of miRNA-21 modulated signal pathways in lung cancer.
FIELD: medicine, pharmacy. SUBSTANCE: invention proposes nontoxic microemulsion of type "oil-in-water" or bioconstant microemulsion consisting of polar phase, nonpolar phase and a mixture of hydrophilic and hydrophobic surface active substance. Polar phase has water and one or more components regulating its polarity properties. Nonpolar phase consists of one or more pharmaceutically acceptable oil. Amount of surface-active substance mixture is up to 15% of emulsion mass. Hydrophobic surface-active substance is taken among the group: lecithin, sphingolipids and galactolipids. Microemulsion is prepared by mixing components in any sequence. Mixture is kept to stand for one or two days up to equilibrium state. Equilibrium can be accelerated by the mold mixture heating at 40 C and stirring or shaking in regular time intervals. Invention can be used for remedy preparation making. EFFECT: minimal amount of surface-active substance used, decreased toxicity of preparations based on microemulsion claimed. 23 cl, 1 dwg, 4 tbl, 4 ex
PURPOSE:To obtain an oxygen carrier, containing a hemoglobin-polyoxyalkylene conjugate, used as an erythrocytic substitute and capable of suppressing cancer multiplying action after injection as compared with that of blood transfusion groups and useful for blood transfusion of patients suffering from cancer. CONSTITUTION:An oxygen carrier, containing a hemoglobin-polyoxyalkylene conjugate, preferably a conjugate having a linking part of a polyoxyalkylene terminal to amino group of hemoglobin expressed by the structural formula (Hb is hemoglobin; n is 1-7). The above-mentioned conjugate is obtained by reacting a hemoglobin solution in 0.5-20wt.%, preferably 0.5-10wt.% concentration with a polyoxyalkylene (preferably 1,000-6,000mol.wt.) in an amount of 1-50mol., preferably 2-10mol. based on 1mol. hemoglobin. The oxygen carrier is preferably used as a freeze-dried pharmaceutical containing the afore- mentioned conjugate and maltose, mannitol and/or glucose in an amount of 0.1-2.0 times based on the conjugate.
Glyburide and Metformin Hydrochloride Tablets combines glyburide and metformin hydrochloride, two antihyperglycemic agents with complementary mechanisms of action, to improve glycemic control in patients with type 2 diabetes. 

Glyburide appears to lower blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which glyburide lowers blood glucose during long-term administration has not been clearly established. With chronic administration in patients with type 2 diabetes, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonylurea hypoglycemic drugs. 

Metformin hydrochloride is an antihyperglycemic agent that improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin hydrochloride decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.